Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights

Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a poor 5-year overall survival rate (~10%). The revolution of immunotherapy in clinical oncology has not substantially changed clinical outcome for patients with PDAC. Despite outstanding efforts, neither immune checkpoint inhibitors (...

Descripción completa

Detalles Bibliográficos
Autores principales: Balsano, Rita, Zanuso, Valentina, Pirozzi, Angelo, Rimassa, Lorenza, Bozzarelli, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136659/
https://www.ncbi.nlm.nih.gov/pubmed/37185406
http://dx.doi.org/10.3390/curroncol30040293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136659/
https://www.ncbi.nlm.nih.gov/pubmed/37185406
http://dx.doi.org/10.3390/curroncol30040293

Ejemplares similares